Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) is set to announce its earnings results before the market opens on Wednesday, August 14th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.11. On average, analysts expect Iterum Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Iterum Therapeutics Price Performance
NASDAQ:ITRM opened at $1.13 on Tuesday. The stock has a market cap of $18.71 million, a PE ratio of -0.43 and a beta of 2.26. Iterum Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $2.50. The stock’s 50-day moving average is $1.24 and its two-hundred day moving average is $1.42.
Analysts Set New Price Targets
Get Our Latest Research Report on Iterum Therapeutics
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Further Reading
- Five stocks we like better than Iterum Therapeutics
- Using the MarketBeat Stock Split Calculator
- How to Invest in Silver: A Beginner’s Guide
- Pros And Cons Of Monthly Dividend Stocks
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.